Published in Neuropsychopharmacology on August 01, 2004
Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function. Biochem Pharmacol (2007) 1.25
TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. Biochem Pharmacol (2009) 1.09
Association of the met66 allele of brain-derived neurotrophic factor (BDNF) with smoking. Psychopharmacology (Berl) (2006) 1.09
The chimeric gene CHRFAM7A, a partial duplication of the CHRNA7 gene, is a dominant negative regulator of α7*nAChR function. Biochem Pharmacol (2011) 1.06
Smoking, Genetics and Schizophrenia: Evidence for Self Medication. J Dual Diagn (2007) 1.04
Differential regulation of alpha7 nicotinic receptor gene (CHRNA7) expression in schizophrenic smokers. J Mol Neurosci (2009) 1.03
Common and unique biological pathways associated with smoking initiation/progression, nicotine dependence, and smoking cessation. Neuropsychopharmacology (2009) 1.03
Alpha7 nicotinic acetylcholine receptors modulate motivation to self-administer nicotine: implications for smoking and schizophrenia. Neuropsychopharmacology (2011) 1.01
α7 Nicotinic Receptor Agonists: Potential Therapeutic Drugs for Treatment of Cognitive Impairments in Schizophrenia and Alzheimer's Disease. Open Med Chem J (2010) 1.00
Cardiovascular disease risk among the poor and homeless - what we know so far. Curr Cardiol Rev (2009) 0.98
Multiple genes in the 15q13-q14 chromosomal region are associated with schizophrenia. Psychiatr Genet (2012) 0.89
High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. Schizophr Res (2008) 0.89
Association of alpha4beta2 nicotinic receptor and heavy smoking in schizophrenia. J Psychiatry Neurosci (2007) 0.88
Recent advances in treating cognitive impairment in schizophrenia. Psychopharmacology (Berl) (2008) 0.87
No evidence for association between 19 cholinergic genes and bipolar disorder. Am J Med Genet B Neuropsychiatr Genet (2007) 0.87
BRAIN MYELINATION IN PREVALENT NEUROPSYCHIATRIC DEVELOPMENTAL DISORDERS: PRIMARY AND COMORBID ADDICTION. Adolesc Psychiatry (2005) 0.86
nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives. Schizophr Res (2016) 0.84
P50 suppression and its neural generators in antipsychotic-naive first-episode schizophrenia before and after 6 months of quetiapine treatment. Schizophr Bull (2012) 0.83
Cholinergic circuits and signaling in the pathophysiology of schizophrenia. Int Rev Neurobiol (2007) 0.82
ACSL6 is associated with the number of cigarettes smoked and its expression is altered by chronic nicotine exposure. PLoS One (2011) 0.80
Genetic Relationship between Schizophrenia and Nicotine Dependence. Sci Rep (2016) 0.80
Association between the 2-bp deletion polymorphism in the duplicated version of the alpha7 nicotinic receptor gene and P50 sensory gating. Eur J Hum Genet (2012) 0.79
Nicotinic receptor contributions to smoking: insights from human studies and animal models. Curr Addict Rep (2015) 0.78
Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625. Psychopharmacology (Berl) (2011) 0.78
P50 amplitude reduction: a nicotinic receptor-mediated deficit in first-degree relatives of schizophrenia patients. Psychopharmacology (Berl) (2011) 0.75
The insertion/deletion polymorphism in the angiotensin-converting enzyme gene and nicotine dependence in schizophrenia patients. J Neural Transm (Vienna) (2016) 0.75
Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet (2010) 8.55
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet (2006) 6.27
DNA methylation profiles in monozygotic and dizygotic twins. Nat Genet (2009) 5.99
Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (Berl) (2006) 3.68
Genome-wide association and meta-analysis of bipolar disorder in individuals of European ancestry. Proc Natl Acad Sci U S A (2009) 3.49
Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther (2004) 3.49
Monozygotic twins exhibit numerous epigenetic differences: clues to twin discordance? Schizophr Bull (2003) 2.76
Nicotine-dependence symptoms are associated with smoking frequency in adolescents. Am J Prev Med (2003) 2.71
Hydrostatic pressure and the actomyosin cortex drive mitotic cell rounding. Nature (2011) 2.68
Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics (2004) 2.37
Single-cell force spectroscopy. J Cell Sci (2008) 2.29
Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Arch Gen Psychiatry (2006) 2.23
CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clin Pharmacol Ther (2006) 2.21
Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. Hum Mol Genet (2008) 2.12
Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. J Neurogenet (2009) 2.07
Control of directed cell migration in vivo by membrane-to-cortex attachment. PLoS Biol (2010) 2.03
Evidence that 'food addiction' is a valid phenotype of obesity. Appetite (2011) 2.02
The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study. Am J Hum Genet (2002) 1.98
Role of ethnicity in antipsychotic-induced weight gain and tardive dyskinesia: genes or environment? Pharmacogenomics (2013) 1.97
Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. J Natl Cancer Inst (2011) 1.97
Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin Pharmacol Ther (2005) 1.96
Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol Biochem Behav (2008) 1.90
Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab (2014) 1.88
The role of CYP2A6 in the emergence of nicotine dependence in adolescents. Pediatrics (2006) 1.83
Age-related decline in white matter tract integrity and cognitive performance: a DTI tractography and structural equation modeling study. Neurobiol Aging (2010) 1.77
5-hmC in the brain is abundant in synaptic genes and shows differences at the exon-intron boundary. Nat Struct Mol Biol (2012) 1.74
Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology (2003) 1.70
Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PLoS Genet (2013) 1.68
Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biol Psychiatry (2002) 1.66
Dopamine for "wanting" and opioids for "liking": a comparison of obese adults with and without binge eating. Obesity (Silver Spring) (2009) 1.65
Association between serotonin transporter gene and borderline personality disorder. J Psychiatr Res (2006) 1.64
Pharmacogenetics of psychotropic drug response. Am J Psychiatry (2004) 1.61
Straight GDP-tubulin protofilaments form in the presence of taxol. Curr Biol (2007) 1.59
Effect of metabolic blockade on the psychoactive effects of dextromethorphan. Hum Psychopharmacol (2010) 1.59
Suicide risk in bipolar patients: the role of co-morbid substance use disorders. Bipolar Disord (2003) 1.59
Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level. Cancer Epidemiol Biomarkers Prev (2011) 1.57
Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. Pharmacogenomics (2007) 1.56
Molecular mechanisms of schizophrenia. Cell Physiol Biochem (2007) 1.53
Transducer binding establishes localized interactions to tune sensory rhodopsin II. Structure (2008) 1.50
Revealing early steps of alpha2beta1 integrin-mediated adhesion to collagen type I by using single-cell force spectroscopy. Mol Biol Cell (2007) 1.49
CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. Biol Psychiatry (2007) 1.48
The c15 ring of the Spirulina platensis F-ATP synthase: F1/F0 symmetry mismatch is not obligatory. EMBO Rep (2005) 1.48
Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metab Dispos (2002) 1.47
Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response. Psychopharmacology (Berl) (2008) 1.46
Diffusion tensor tractography findings in schizophrenia across the adult lifespan. Brain (2010) 1.43
Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence. Pharmacogenet Genomics (2005) 1.43
Connexin 50 gene on human chromosome 1q21 is associated with schizophrenia in matched case control and family-based studies. J Med Genet (2007) 1.42
Measuring cell adhesion forces of primary gastrulating cells from zebrafish using atomic force microscopy. J Cell Sci (2005) 1.42
Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. Hum Mutat (2008) 1.42
Disc1 point mutations in mice affect development of the cerebral cortex. J Neurosci (2011) 1.40
Pharmacogenetics in psychiatry satellite meeting at the American College of Neuropsychopharmacology, 2000. Neuropsychopharmacology (2002) 1.39
A conceptual history of Koro. Transcult Psychiatry (2007) 1.39
Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study. Psychopharmacology (Berl) (2004) 1.39
An association of CYP2A6 genotype and smoking topography. Nicotine Tob Res (2007) 1.37
A new technical approach to quantify cell-cell adhesion forces by AFM. Ultramicroscopy (2006) 1.37
Molecular genetics of nicotine metabolism. Handb Exp Pharmacol (2009) 1.36
Reproducibility of the nicotine metabolite ratio in cigarette smokers. Cancer Epidemiol Biomarkers Prev (2012) 1.34
Movement directionality in collective migration of germ layer progenitors. Curr Biol (2010) 1.33
CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking. Cancer Epidemiol Biomarkers Prev (2006) 1.33
Reward sensitivity and the D2 dopamine receptor gene: A case-control study of binge eating disorder. Prog Neuropsychopharmacol Biol Psychiatry (2007) 1.31
Genetic and environmental influences on the ratio of 3'hydroxycotinine to cotinine in plasma and urine. Pharmacogenet Genomics (2009) 1.28
Cytochrome P450 enzymes in the brain: emerging evidence of biological significance. Trends Pharmacol Sci (2011) 1.28
Early age at onset as a risk factor for poor outcome of bipolar disorder. J Psychiatr Res (2003) 1.27
Bacteriorhodopsin folds into the membrane against an external force. J Mol Biol (2006) 1.26
Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. Pharmacogenet Genomics (2013) 1.24
The c13 ring from a thermoalkaliphilic ATP synthase reveals an extended diameter due to a special structural region. J Mol Biol (2009) 1.23
Three-dimensional culture and cAMP signaling promote the maturation of human pluripotent stem cell-derived hepatocytes. Development (2013) 1.23
Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology (2002) 1.23
Nicotine metabolism and CYP2A6 activity in a population of black African descent: impact of gender and light smoking. Drug Alcohol Depend (2006) 1.23
Characterization and comparison of nicotine and cotinine metabolism in vitro and in vivo in DBA/2 and C57BL/6 mice. Mol Pharmacol (2006) 1.21
Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry (2012) 1.20
Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model. Hum Mol Genet (2009) 1.18
N-methyl-D-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: Polymorphisms and mRNA levels. Schizophr Res (2006) 1.18
Bupropion for smoking cessation in African American light smokers: a randomized controlled trial. J Natl Cancer Inst (2012) 1.17
CYP2A6 genetic variation and potential consequences. Adv Drug Deliv Rev (2002) 1.17
Quantifying cellular adhesion to extracellular matrix components by single-cell force spectroscopy. Nat Protoc (2010) 1.16
Conformational adaptability of Redbeta during DNA annealing and implications for its structural relationship with Rad52. J Mol Biol (2009) 1.16
Decision-making deficits and overeating: a risk model for obesity. Obes Res (2004) 1.16
Locating ligand binding and activation of a single antiporter. EMBO Rep (2005) 1.15
Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR. Int J Epidemiol (2004) 1.14
A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent. Pharmacogenet Genomics (2008) 1.14
Drug-metabolizing cytochrome P450s in the brain. J Psychiatry Neurosci (2002) 1.14
Nicotine self-administration in mice is associated with rates of nicotine inactivation by CYP2A5. Psychopharmacology (Berl) (2006) 1.14
The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex. Cancer Epidemiol Biomarkers Prev (2013) 1.13
Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state. Pharmacogenet Genomics (2013) 1.12
The oligomeric state of c rings from cyanobacterial F-ATP synthases varies from 13 to 15. J Bacteriol (2007) 1.11
Microarray analysis of the developing cortex. J Neurobiol (2006) 1.11
Contributions of galectin-3 and -9 to epithelial cell adhesion analyzed by single cell force spectroscopy. J Biol Chem (2007) 1.10
Linkage of M5 muscarinic and alpha7-nicotinic receptor genes on 15q13 to schizophrenia. Neuropsychobiology (2004) 1.10
Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method. Pharmacogenet Genomics (2005) 1.10
Factors influencing cotinine half-life during smoking abstinence in African American and Caucasian women. Nicotine Tob Res (2002) 1.08
Serotonin transporter polymorphisms and persistent, pervasive childhood aggression. Am J Psychiatry (2006) 1.08
Nicotine physical dependence and tolerance in the mouse following chronic oral administration. Psychopharmacology (Berl) (2004) 1.08
Pharmacogenetics of nicotine metabolism in twins: methods and procedures. Twin Res (2004) 1.08